The Suppressed Decade: How Modern Psychedelic Research Got Erased

How decades of legitimate psychedelic research were shut down by the 1970 Controlled Substances Act, what was lost, and how the science finally came back.

By The Microdose Movement · April 10, 2026

By 1968, psilocybin was one of the most-studied compounds in academic psychiatry. By 1971, it was effectively illegal to study. By 1972, almost every research program that had been running for the previous decade had shut down or gone underground. By the late 1970s, an entire field of medicine had been erased from the institutional landscape and would not return for thirty years.

This article is about how that happened, what got lost in the process, and why understanding this history matters for anyone engaging with the modern revival of these compounds. It is not a conspiracy theory. It is the actual sequence of political and bureaucratic decisions that took a legitimate area of scientific research and put it in a vault.

What the field looked like before 1970

By the late 1960s, psychedelic research was a real and active branch of psychiatry and psychology. Sandoz Pharmaceuticals was distributing pure synthetic psilocybin to qualified researchers around the world under the brand name Indocybin. LSD had been used in clinical settings to treat alcoholism, depression, end-of-life anxiety, and various neuroses, with reported success rates that, in retrospect, look comparable to what modern research is finding now.

A non-exhaustive list of what was happening:

The Spring Grove Hospital in Maryland was running formal clinical trials of LSD-assisted therapy for alcoholism, treatment-resistant depression, and anxiety in cancer patients.
The Saskatchewan psychiatrist Humphry Osmond (the man who coined the word “psychedelic” in 1957) had treated thousands of alcoholics with LSD and reported abstinence rates of 40–60% at one-year follow-up.
Stanislav Grof was conducting his pioneering work on LSD-assisted psychotherapy at the Maryland Psychiatric Research Center, eventually documenting over 4,000 sessions.
Walter Pahnke had published his famous Good Friday Experiment showing that psilocybin could occasion genuine mystical experiences in theology students.
The Harvard Psilocybin Project had run dozens of studies on creativity, religious experience, and rehabilitation.
The International Foundation for Advanced Study was demonstrating that psychedelics could support creative problem-solving in scientists and engineers.
Hundreds of academic papers were being published every year. Conferences were being held. Textbooks were being written.

This was not a fringe movement. It was a well-funded, peer-reviewed area of psychiatric research with significant institutional support.

What changed in 1970

Three things came together at the same moment.

First, the cultural backlash. Timothy Leary had become a public figure in a way that frightened the establishment. His “tune in, turn on, drop out” framing made psychedelics into a symbol of the 1960s counterculture, the anti-war movement, and the rejection of mainstream American values. The political class saw psychedelics not as medicine but as a threat to social order.

Second, the safety panic. A small number of high-profile bad outcomes — accidents, psychotic breaks, criminal cases involving people who had used LSD — got enormous media coverage. Whether the substances actually caused these outcomes or merely happened to be in the room during them was rarely examined carefully. The reporting created the impression that psychedelics were vastly more dangerous than the research suggested.

Third, and most consequentially, the Controlled Substances Act. Signed into law by President Nixon in October 1970, the CSA created a five-tier scheduling system for drugs based on their accepted medical use and abuse potential. Schedule I — the most restrictive category — was defined as substances with “no currently accepted medical use” and “high potential for abuse.”

Psilocybin, LSD, mescaline, peyote, MDMA, DMT, and most other psychedelic compounds were placed in Schedule I.

The classification was not based on a careful review of the evidence. It was a political decision made in a particular cultural moment. Years later, John Ehrlichman, one of Nixon’s closest advisors, told the journalist Dan Baum in a 1994 interview that the Nixon administration had specifically targeted hippies and Black communities by criminalizing the substances most associated with them. The quote, published in Harper’s Magazine in 2016, is famous now:

“We knew we couldn’t make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities.”

The CSA was the legal mechanism that turned that political project into binding law.

What Schedule I actually meant for research

Once psilocybin was in Schedule I, conducting research on it became almost impossible. The regulatory requirements stacked up like this:

Researchers had to obtain a Schedule I license from the DEA, which took years to approve and required extensive justification.
Institutional Review Boards became extremely reluctant to approve studies involving Schedule I substances.
Universities lost interest in funding research that might attract negative public attention.
Federal funding agencies (NIH, NIMH) effectively stopped granting money for psychedelic research.
The compounds themselves became extraordinarily difficult to obtain legally. Sandoz stopped distributing them. Researchers could not get supply.
Anyone caught in possession without proper authorization faced felony charges.

The combined effect was that even researchers who wanted to continue the work could not. The infrastructure that had supported psychedelic research in the 1960s — the funding, the supply chain, the institutional buy-in, the trained personnel — all evaporated within a few years. By the late 1970s, the field was effectively dead.

The published literature went silent. The 1,000+ papers that had appeared during the 1960s slowed to a few stragglers per year. Researchers who had spent careers studying these compounds either retired, switched fields, or continued their work underground in countries with looser regulations. A generation of trained psychedelic researchers aged out of the system without anyone replacing them.

What got lost

The cost of the suppression is hard to measure precisely because we cannot run a counterfactual experiment. But we can list what stopped.

The clinical work on alcoholism. Humphry Osmond and his collaborators had been treating alcoholics with LSD-assisted therapy for almost two decades and reporting outcomes that exceeded what conventional treatments achieved. That work was abandoned. It would be forty years before similar studies were attempted again.

The end-of-life anxiety research. The Spring Grove Hospital had documented that LSD could significantly reduce anxiety and depression in terminally ill cancer patients. The studies were halted. Patients who could have benefited were left without the option for the next four decades.

The psychiatric depression research. Multiple research groups had been investigating LSD and psilocybin for treatment-resistant depression with promising early results. All of it stopped. The first modern psilocybin-for-depression trial would not be published until 2016.

The training pipeline. A generation of psychiatrists who had trained in psychedelic-assisted therapy aged out of the field without passing on the practical knowledge. When the modern revival began in the 2000s, researchers had to relearn techniques that had been working in the 1960s.

The relationship with the indigenous traditions. Maria Sabina and the other curanderos who had shared their knowledge with the modern world saw their traditions become criminalized and their sacred practices reframed as drug use. The relationship between indigenous keepers of these medicines and the modern world was set back by decades.

The institutional memory. Universities, hospitals, and funding bodies developed policies and reflexes that treated psychedelic research as unserious or dangerous. Those reflexes are still present in many institutions today, even as the science has long since reversed its position.

How the research came back

The modern revival was not a single event. It was a slow, careful, methodical process of rebuilding institutional credibility for a field that had been politically discredited. A few key moments:

1986: MAPS is founded. Rick Doblin establishes the Multidisciplinary Association for Psychedelic Studies as a 501(c)(3) nonprofit specifically dedicated to advancing legal psychedelic research. For most of its first twenty years, MAPS operated mostly as an advocacy organization because the regulatory climate made actual research nearly impossible.

1990s: The first modern studies. Rick Strassman conducted DMT studies at the University of New Mexico in the early 1990s — the first formal human psychedelic research in the United States in over twenty years. The studies were small, the regulatory burden was enormous, but they reopened a door.

2000: Heffter Research Institute funds early work at Johns Hopkins. A handful of brave researchers began applying for the bureaucratic permissions needed to study psilocybin formally.

2006: The Griffiths paper. Roland Griffiths and colleagues at Johns Hopkins publish “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance” in Psychopharmacology. It is the first major modern psilocybin paper in a respected journal. The dam starts to crack.

2011: The Imperial College team begins. Robin Carhart-Harris and David Nutt assemble the Imperial College London team that will eventually produce most of the foundational neuroscience of the modern field.

2018: FDA breakthrough therapy designation. The FDA grants psilocybin-assisted therapy “breakthrough therapy” status for treatment-resistant depression, signaling that the regulatory environment has shifted decisively. This designation effectively says: this might actually be an important treatment.

2021: The NEJM head-to-head trial. The Imperial team publishes their study comparing psilocybin to escitalopram in The New England Journal of Medicine. Psilocybin matches the SSRI on the primary outcome and beats it on several secondary measures. The legitimacy of the field is no longer in question.

2024: State-level legalization expands. Oregon, Colorado, and a growing list of cities begin legalizing or decriminalizing psilocybin for therapeutic and personal use.

The modern revival is the slow recovery of something that was suppressed, not the discovery of something new. Every researcher working on psilocybin today is, in some sense, picking up work that was interrupted by the Controlled Substances Act.

What this history asks of us

A few things worth carrying.

The science was always there. The research that suddenly became respectable in the 2010s was, in most cases, recovering what had been working in the 1960s. The new findings are extending and refining the old findings, not discovering them from scratch.

The suppression was political, not scientific. Knowing this matters for how you respond to the stigma you may still encounter from family, doctors, or institutions that haven’t caught up. The position that psychedelics are dangerous is a holdover from a 1970 political decision, not a current scientific consensus.

The cost was real and measurable. Forty years of research that did not happen. People who could have been helped and were not. Knowledge that had to be rediscovered. None of this was inevitable. It was the result of specific decisions that could have gone differently.

The window is open now and should not be wasted. The Microdose Movement exists because the cultural moment is finally permitting a serious conversation about these tools. That permission was hard-won, slow to arrive, and not guaranteed to last. What we do with this window matters.

Sources and Further Reading

Bonson, K. R. (2018). “Regulation of human research with LSD in the United States (1949–1987).” Psychopharmacology, 235(2), 591–604.
Doblin, R. (1991). “Pahnke’s ‘Good Friday Experiment’: a long-term follow-up and methodological critique.” Journal of Transpersonal Psychology, 23(1), 1–28.
Dyck, E. (2008). Psychedelic Psychiatry: LSD from Clinic to Campus. Johns Hopkins University Press.
Griffiths, R. R., et al. (2006). “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.” Psychopharmacology, 187(3), 268–283.
Pollan, M. (2018). How to Change Your Mind. Penguin.
Baum, D. (2016). “Legalize It All: How to win the war on drugs.” Harper’s Magazine, April 2016.

A Brief History of Microdosing — the longer view
Why Now: The Cultural Window for Root-Cause Healing — what is happening in the present moment
Imperial College London Psilocybin Research — the modern team that helped end the dark age
James Fadiman and the Modern Microdosing Protocol — one of the last researchers from the 1960s era who lived to see the revival

The Microdose Movement is an educational community, not a medical provider. Nothing in this article is medical advice.